FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and concerns a hyperglycolised version of parental interferon type 1 wherein the hyperglycolised version of parental interferon type 1 has been modified to include at least three additional glycolised sites.
EFFECT: invention provides prolonged preservation in the subject in comparison with parental interferon type 1 that allows decreasing a dosage.
93 cl, 2 ex, 32 dwg, 12 tbl
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES RAISED AGAINST α-INTERFERON | 2002 |
|
RU2314317C2 |
USING TYPE III PEGYLATED INTERFERONS FOR TREATING HEPATITIS C | 2009 |
|
RU2496514C2 |
SINGLE-CHAIN TRAIL-RECEPTOR AGONIST PROTEINS | 2015 |
|
RU2699285C2 |
VARIANTS OF GAMMA-INTERFERON POLYPEPTIDE | 2002 |
|
RU2296130C2 |
SINGLE-STRANDED CD40 RECEPTOR AGONIST PROTEINS | 2016 |
|
RU2745801C2 |
COMPOSITIONS AND METHODS OF TREATING DISEASES AND DISORDERS ASSOCIATING CYTOKINE SIGNAL TRANSMISSION | 2006 |
|
RU2426742C2 |
FUSED IMMUNOGLOBULIN PROTEINS | 2008 |
|
RU2530168C2 |
IMPROVED METHODS OF TREATING VASCULARISED MALIGNANT TUMORS | 2015 |
|
RU2692248C2 |
VERSIONS OF GLA DOMAIN OF FACTOR VII OR VIIa | 2004 |
|
RU2373282C2 |
MOLECULES SIMILAR TO FACTOR VII OR VIIA | 2001 |
|
RU2278123C2 |
Authors
Dates
2010-06-27—Published
2005-08-08—Filed